ASCO Daily News

Top Stories

Bevacizumab or Cetuximab with FOLFOX

ALTTO Trial Findings Raise Questions on Approach to Drug Development in Early Breast Cancer

Durable Responses to Ibrutinib Seen in Patients with Chronic Lymphocytic Leukemia

Extraordinary Responders Drive Concept of Basket Trial Design

No Benefit Seen with Cetuximab Addition in Patients with mCRC, RAS-Activating Mutation